A prospective, observational, multicenter study assessing the safety and efficacy of von Willebrand Factor Concentrate (Wilate®) in von Willebrand disease patients in routine clinical use.
Latest Information Update: 11 Jan 2017
Price :
$35 *
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2017 New trial record
- 06 Dec 2016 Results of interim analysis (n=13)assessing safety and efficacy of Von Willebrand Factor Concentrate (Wilate) for von-Willebrand-disease patients in routine clinical settings presented at the 58th Annual Meeting and Exposition of the American Society of Hematology